[go: up one dir, main page]

WO2007039123A3 - Combination therapy comprising an nk-3 antagonist and an antipsychotic agent - Google Patents

Combination therapy comprising an nk-3 antagonist and an antipsychotic agent Download PDF

Info

Publication number
WO2007039123A3
WO2007039123A3 PCT/EP2006/009182 EP2006009182W WO2007039123A3 WO 2007039123 A3 WO2007039123 A3 WO 2007039123A3 EP 2006009182 W EP2006009182 W EP 2006009182W WO 2007039123 A3 WO2007039123 A3 WO 2007039123A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist
antipsychotic agent
combination therapy
therapeutic administration
antipsychotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/009182
Other languages
French (fr)
Other versions
WO2007039123A2 (en
Inventor
Lee Anthony Dawson
Martin Lowy
David Graeme Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of WO2007039123A2 publication Critical patent/WO2007039123A2/en
Publication of WO2007039123A3 publication Critical patent/WO2007039123A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of an NK3 antagonist or a pharmaceutically acceptable salt thereof to a patient receiving therapeutic administration of an antipsychotic agent.
PCT/EP2006/009182 2005-09-22 2006-09-20 Combination therapy comprising an nk-3 antagonist and an antipsychotic agent Ceased WO2007039123A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71935205P 2005-09-22 2005-09-22
US06/719,352 2005-09-22

Publications (2)

Publication Number Publication Date
WO2007039123A2 WO2007039123A2 (en) 2007-04-12
WO2007039123A3 true WO2007039123A3 (en) 2007-06-21

Family

ID=37898829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009182 Ceased WO2007039123A2 (en) 2005-09-22 2006-09-20 Combination therapy comprising an nk-3 antagonist and an antipsychotic agent

Country Status (1)

Country Link
WO (1) WO2007039123A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057130A1 (en) 2005-09-21 2007-11-14 Astrazeneca Ab ALKYL SULFOXIDE QUINOLINS AND A PHARMACEUTICAL COMPOSITION
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
AU2009219174B2 (en) 2008-02-28 2014-04-03 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
EP2588630A4 (en) 2010-07-02 2013-12-25 Univ Virginia Patent Found MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
EA027743B1 (en) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
CA3049464A1 (en) * 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
EP4096508A4 (en) * 2020-01-30 2024-03-27 Javed, Mohammad COMBINATION THERAPIES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
US20250270330A1 (en) * 2022-04-25 2025-08-28 Kallyope, Inc. Treatment of headache disorders with nk3 modulators
AU2024257749A1 (en) 2023-04-18 2025-11-13 Kallyope, Inc. Nk3 modulators and uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031037A1 (en) * 1998-11-20 2000-06-02 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005097794A1 (en) * 2004-04-06 2005-10-20 Janssen Pharmaceutica N.V. Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2006013050A1 (en) * 2004-08-06 2006-02-09 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists against schizophrenia
WO2006016192A2 (en) * 2004-08-09 2006-02-16 Merck Sharp & Dohme Limited Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
WO2006050991A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
WO2006050992A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031037A1 (en) * 1998-11-20 2000-06-02 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
WO2005002577A1 (en) * 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
WO2005097794A1 (en) * 2004-04-06 2005-10-20 Janssen Pharmaceutica N.V. Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
WO2006013050A1 (en) * 2004-08-06 2006-02-09 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists against schizophrenia
WO2006016192A2 (en) * 2004-08-09 2006-02-16 Merck Sharp & Dohme Limited Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
WO2006050991A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
WO2006050992A1 (en) * 2004-11-12 2006-05-18 Smithkline Beecham Corporation Compounds having activity at nk3 receptor and uses thereof in medicine
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MELTZER H ET AL: "NK3 receptor antagonists for the treatment of schizophrenia", DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES, vol. 3, no. 4, 2006, pages 555 - 560, XP002428807 *
PETITET F ET AL: "The nonpeptide NK-2 antagonist SR 48968 is also a NK-3 antagonist in the guinea pig but not in the rat", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 191, no. 1, 1993, pages 180 - 187, XP002428808 *

Also Published As

Publication number Publication date
WO2007039123A2 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
AP2037A (en) Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
MX374396B (en) SUBLINGUAL FENTANYL SPRAY.
IL184125A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009017837A3 (en) Sublingual fentanyl spray
MX2009004516A (en) Methods and combination therapies for treating alzheimer's disease.
AU2003297621A8 (en) Medical devices for delivery of therapeutic agents
IL184425A0 (en) Cxcr4 antagonists for the treatment of medical disorders
HUS1500058I1 (en) Benzoxazine-containing drug combination for the treatment of respiratory diseases
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
IL173351A0 (en) Therapy of ocular disorders
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent
PL397023A1 (en) Therapeutic agent for AIDS treatment
TWI369988B (en) New pharmaceutically active compounds for the treatment of respiratory diseases
WO2007107696A3 (en) Pharmaceutically acceptable salts and polymorphic forms
GB0408752D0 (en) Therapeutic treatment
WO2005000247A3 (en) 4-carboxamido quinoline derivatives for use as nk-2 and nk-3
WO2004066951A3 (en) Quinoline derivatives as nk-2 and nk-3 receptor antagonists
WO2004066950A3 (en) Quinoline derivatives as nk-2 and nk-3 receptor antagonists
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0411762D0 (en) Therapeutic medical device
GB0422812D0 (en) Medical needle safety devices
GB0422810D0 (en) Medical needle safety devices
GB0425281D0 (en) Therapeutic treatment
GB0404339D0 (en) Therapeutic treatment

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06792201

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06792201

Country of ref document: EP

Kind code of ref document: A2